PNT2258: Phase II started

ProNAi began the open-label, U.S. Phase II Wolverine trial to evaluate 120 mg/m 2 IV PNT2258 on days 1-5 of a 21-day cycle for up to 8 induction cycles in about 60 patients. Patients who benefit from ...